

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	PPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/335,581	09/335,581 06/18/1999		JASON D. BANNAN	2016-4010US2	6638	
27123	7590	02/12/2003				
		EGAN, L.L.P.	EXAMINER			
345 PARK AVENUE NEW YORK, NY 10154				HINES, J	HINES, JANA A	
				ART UNIT	PAPER NUMBER	
				1645	25	
				DATE MAILED: 02/12/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Advisory Action**

Applicati n N .	Applicant(s)
09/335,581	BANNAN ET AL.
Examiner	Art Unit
Ja-Na Hines	1645

-- The MAILING DATE of this communication appears on the cover sheet with the corresp ndence address --

THE REPLY FILED 31 July 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a

10.	Other: LYNETTE R. F. SMITH SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600
	The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.  Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)
8.	Claim(s) withdrawn from consideration:  The proposed drawing correction filed on is a) energyed or _b) disconnected by the Freedings.
	Claim(s) rejected: 50-55.
	Claim(s) objected to: <u>None</u> .
	Claim(s) allowed: None.
	The status of the claim(s) is (or will be) as follows:
	explanation of how the new or amended claims would be rejected is provided below or appended.
7.🖂	raised by the Examiner in the final rejection.  For purposes of Appeal, the proposed amendment(s) a)⊠ will not be entered or b)□ will be entered and an
6.	The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly
5.	The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:
4.	Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
3.	Applicant's reply has overcome the following rejection(s):
	NOTE: <u>See Continuation Sheet</u> .
(d	they present additional claims without canceling a corresponding number of finally rejected claims.
(c	) ☑ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(b	) 🔲 they raise the issue of new matter (see Note below);
(a	) Multiply they raise new issues that would require further consideration and/or search (see NOTE below);
2.🖂	The proposed amendment(s) will not be entered because:
1.	A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
fee hav fee und (2) as s	tensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension e been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension ler 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or let forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if lied, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).
b) [	
a) [	The period for reply expires 3 months from the mailing date of the final rejection.
Exam	ination (RCE) in compliance with 37 CFR 1.114.  PERIOD FOR REPLY [check either a) or b)]
final re	ejection under 37 CFR 1.113 may <u>only</u> be either: (1) a timely filed amendment which places the application in tion for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued



Continuation of 2. NOTE: The amendment will not be entered because it raises new issues which require further consideration; neither do the amendments place the application in better form. The amendment is now drawn to a non-toxic peptide, previously the claims were drawn to either a toxic or non-toxic peptide. Furthermore the claims recite a negative limitation wherein the peptide is not SEB or SEC or other native toxin, and previously there was no such limitation. Therefore, the claims require additional consideration with respect to the toxicity and orgin of the peptide. Thus, the amendment does not simplify the issues and will not be entered.